ATS Clinical Year in Review: Cystic Fibrosis and Lung Cancer
Core topics in Cystic Fibrosis and Lung Cancer are explored in this interactive module. Emerging leaders in the field present carefully-curated reviews of the current literature on critical, state-of-the-art topics and evolving concepts. After completing this module, learners will better understand novel concepts in each specific domain that we hope will translate to improved patient care.
This product is part of Clinical Year in Review series presented at the 2022 ATS International Conference.
Grant Support: This educational module is supported by independent medical educational grants from AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc, Merck & Co., Insmed Incorporated, and Vertex Pharmaceuticals.
Clinicians (physicians, nurses, fellows, residents), researchers, administrators, and policymakers: anyone involved in the delivery of care and the science of patients with Cystic Fibrosis and/or Lung Cancer.
After successfully completing this module, learners will be able to:
- Discuss the newest data and analyses related to Cystic Fibrosis research and Lung Cancer research
- Identify and apply the most current clinical care recommendations to manage the care of patients with Cystic Fibrosis
- Identify and apply the most current clinical care recommendations to manage the care of patients with Lung Cancer
- Independently review the literature referenced in this module
|ATS International Conference Committee||International Conference Committee||Various||Planner||See Planner Disclosure Summary: https://bit.ly/coisummary|
|ATS Education Committee||Education Committee||Various||Planner||See Planner Disclosure Summary: https://bit.ly/coisummary|
|Jose L. Gomez, MS, MD, ATSF||Associate Professor of Medicine||Yale University||Chair, Clinical Year in Review||No relevant financial relationships to disclose|
|Rupal J. Shah, MD, MSCE||Assistant Professor of Medicine||University of California San Francisco||Chair, Clinical Year in Review||No relevant financial relationships to disclose|
|Juliana C. Ferreira, MD, PhD, ATSF||Associate Professor||University of Sao Paulo||Chair, Clinical Year in Review||No relevant financial relationships to disclose|
|Christine Marie Bojanowski, MD||Assistant Professor of Medicine||Tulane University School of Medicine||Presenter 1: Cystic Fibrosis||Phylaxis Bioscience, LLC: Consultant|
|Neal Navani, MD, MSc, PhD||Associate Professor||University College London Hospital||Presenter 2: Lung Cancer||Amgen: Speaker/faculty - non-promotional purpose|
AstraZeneca: Speaker/faculty - non-promotional purpose
BMS: Advisory Committee for non-promotional
Janssen Inc.: Advisory Committee for non-promotional
Lilly: Advisory Committee for non-promotional
Merck Sharp & Dome: Advisory Committee for non-promotional
Olympus: Advisory Committee for non-promotional
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.
This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions to Receive Credit
To earn credit for this course, follow these instructions:
- Launch and complete all modules by viewing every page in the module.
- After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
- Complete the Course Evaluation.
- Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
- To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.
- 0.75 ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 0.75 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Participation